Hostname: page-component-6bf8c574d5-t27h7 Total loading time: 0 Render date: 2025-02-16T17:15:25.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment with depressions in Parkinson's disease

Published online by Cambridge University Press:  18 September 2015

R.A.V. Smit
Get access Rights & Permissions [Opens in a new window]

Summary

People with Parkinson's disease often suffer from depressions. Treatment of these depressions requires the use of antidepressants. The advanced age of most patients, however, can put limitations on the range of suitable antidepressants. Moreover, the drug should not aggravate Parkinson's disease. Many patients suffering from Parkinson's disease are currently prescribed selegiline. This drug is commonly considered to be a contraindication for antidepressants.

In this article, criteria for the choice of a suitable psychofarmacon are discussed. In particular suggestions are offered for the treatment of patients who are already taking selegiline.

Keywords

Parkinson's diseasedepressionanti-depressantsselegilinedrug interactionsZiekte van Parkinsondepressieanti-depressivaselegilinegeneesmiddelinteracties
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 6 , Issue 2 , June 1994 , pp. 25 - 28
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

3.Cummings, JL. Depression and Parkinson's disease: A review. Am Journal Psychiat 1992; 149:443–54.Google ScholarPubMed
11.Birkmayer, W. Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta neurol scand 1983; suppl 5: 103–6.CrossRefGoogle Scholar
12.Farmacotherapeutisch Kompas, Amstelveen: Centrale Medisene Pharmaceutische Commissie van de Ziekenfondsraad 1992:86–91.Google Scholar
13.Andersen, J, Aabro, E, Gulmaan, N, Hjelmstedt, A, Pedersen, HE. Anti-depressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-Dopa. Acta neurol scand 1980; 62:210–9.CrossRefGoogle ScholarPubMed
14.Laitinen, L. Desipramine in treatment of Parkinson's disease. Acta neurol scand 1969; 45:109–13.CrossRefGoogle ScholarPubMed
15.Strang, RR. Imipramine in treatment of Parkinsonism: A double blind placebo study. Br med J 1965; 2:33–4.CrossRefGoogle ScholarPubMed
18.Swinkels, JA. Mogelijkheden en gevaren van anti-depressiva bij ouderen. Diagnostiek, therapie en onderzoek in de neuropsychiatrie. Stichting Neuropsychiatrie. Maastricht: symposium IGBP, 1991:21–36.Google Scholar
20.Salzman, C. Anti-depressants. Clin geriat Med 1990; 6:399–410.CrossRefGoogle Scholar
24. Edwards, M. Adverse interaction of levodopa with tricyclic antidepressants. The Practitioner 1982; 226:1447–9.Google ScholarPubMed
25.Cavanaugh von Ammon, S. Drug- drug interactions of fluoxetine with tricyclics. Psychosomatics 1990; 31:273–6.CrossRefGoogle Scholar
26.Crewe, HK, Lennard, MS, Tucker, GT, Woods, FR, Haddock, RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J clin Pharmac 1992; 34:262–5.CrossRefGoogle ScholarPubMed
27.Chrisp, P, Mammen, G, Sorkin, EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential on Parkinson's disease. Drugs Aging 1991; 1:228–48.CrossRefGoogle ScholarPubMed
29.Jansen Steur, ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43:211–3.CrossRefGoogle Scholar
30.Meitzer, HY, Young, M, Metz, J, Fang, VS, Schyve, PM, Arora, RC. Extrapyrimidal side effects and increased serum prolactin following fluoxetine, a new anti-depressant. J neural Transm 1979; 42:165–75.CrossRefGoogle Scholar
32.Baldessarini, RJ, Marsch, E. Fluoxetine and side effects. Arch gen Psychiat 1990; 47:191–2.CrossRefGoogle ScholarPubMed
35.Mann, JJ, Fox Aarons, S, Wilner, PJ, et al.A controlled study of the antidepressant efficacy and side effects of (-)deprenyl. Arch gen Psychiat 1989; 46:45–50.CrossRefGoogle ScholarPubMed
36.Mendlewicz, J, Youdim, MBH. L-deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiat 1983; 142:508–11.CrossRefGoogle ScholarPubMed
40.Suchowersky, O, de Vries, JD. Interaction of fluoxetine and selegiline. Can J Psychiat 1990; 35:571–2. Identiek aan: Possible interactions between deprenyl and Prozac. Canadion J neurol Sci 1990;17:352-3.CrossRefGoogle ScholarPubMed
41.Feighner, JP, Boyer, WF, Tyker, DL, Neborsky, RJ. Adverse consequences of fluoxetine - MAOI combination therapy. J clin Psychiat 1990; 51:222–5.Google ScholarPubMed
44.Sternbach, H. The serotonin syndrome. Am J Psychiat 1991; 48:705–13.Google Scholar
48.Marley, E, Wozniak, KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 1983;13:735–49.CrossRefGoogle ScholarPubMed